

#### ARBEITSKREIS MEDIZINISCHER ETHIK-KOMMISSIONEN

IN DER BUNDESREPUBLIK DEUTSCHLAND E.V.

## CLINICAL TRIAL REGULATION AND ETHICS-COMMITTEE PREPAREDNESS

Germany

DIA - Clinical Trial Regulation 2-3 December 2019, AMS

Prof. Dr. Joerg Hasford

President, Association of Medical Ethics Committees in Germany E-Mail: has-ethik@ibe.med.uni-muenchen.de

#### **Conflicts of Interest and Caveat**

- **✓** There are no conflicts of interest to declare.
- ✓ The views expressed here do not necessarily represent exactly those of AKEK Germany.



#### **Structure**

- Introduction: Current situation in Germany
- Provisions of the CTR
- Implementation of the CTR in Germany
- Registration requirements for ECs
- Responsibilities NCAs / ECs
- Conclusions

#### Present state of trial approval in Germany

- The German Medicines Act and the GCP-Ordinance implemented the CTD 2001/20/EU in Germany in 2004.
- Assessment of the application dossier independently by MEC and NCA.
- Approval by MEC needed to start a drug trial.
- Only national laws and regulations applicable.
- Option for oral discussions with sponsor.
- Truely independent and autonomous MECs, regulated by state law.



#### **Tasks of Medical Ethics Committees**

- To ensure the protection of the rights, safety and well-being of human subjects involved in a trial and
- To provide public assurance of the protection
- Reviewing and approving the trial protocol, the suitability of the investigators, facilities, and the methods and material to be used in obtaining informed consent.



### CTR 536/2014 Role of Ethics Committees

- The ethical review shall be performed by an ethics committee (EC) in accordance with the law of the MSc. The review by the EC may encompass aspects addressed in Part I and in Part II as appropriate for each MSc. (CTR Art. 4)
- Contradiction to DoH and ICH-GCP
- In Germany ECs will review Part I and II.



### **Application Dossier for Initial Application**

- Part I: Trial protocol, scientific background, risk (harm) benefit assessment, IB, details specified in Article 6 and Annex I
- Part II: Informed Consent material, qualification of investigators and suitability of study sites (centres), insurance etc., details specified in Article 7 and Annex I
- **Part I:** Evaluated by all MS concerned, reporting MS coordinates the assessment and provides 'single decision'.

J. Hasford
München

**Part II:** Evaluated by all MS concerned, each MS provides **its** decision.

#### **Ethics Committee - Definition**

'an independent body in a Member State established in accordance with national law and empowered to give opinions for the purposes of this Regulation, taking into account the views of lay-persons, in particular patients or patients organisations'.

CTR Art.2 2. (11)



#### THE IMPLEMENTATION LAW

- In November 2016 the German Parliament passed the implementation law for the CTR 536/2014.
- The law speficies the structure and composition of ECs, tasks and responsibilities of the NCAs and the ECs, and their cooperation.

#### **Implementation Law: Registration of MECs**

#### Requirements (AMG § 41 neu)

- 1. Documented state of the art expertise of the members,
- 2. Multidisciplinary composition: at least one lawyer, one person with expertise in medical ethics, three practising physicians(one pharmacologist), one biostatistician and one lay person,
- 3. Assured equal access for female and male members to the EC,

# Implementation Law: Registration of ECs Requirements (§ 41 neu)

- 5. By-laws covering internal procedures, transparency, decision-making etc.,
- 6. Business office with adequately qualified staff,
- 7. Adequate technical equipment and performance,
- 8. Proof of the independence of the members and external experts ( = no Col) 11

## Responsibilities of EC and NCA

- ➤ Part I will be assessed jointly by NCA and EC, NCA taking the lead → lead coordinator.
- > Part II will be assessed solely by competent EC.

➤ The final decision (Art.8) by the MS Germany will be provided by the competent German NCA, respecting the opinion of the competent EC.

#### **Further News and Innovations**

- > About 35 MECs got registered up to now.
- ➤ The MECs will be randomly allocated to the approx. 1000 applications/year.
- About 190 applications have been successfully assessed under the conditions and timelines of the CTR.
- > Sponsors had occasionaly problems with the 12 calender day limit for responding.
- ➤ NCA and MEC will offer scientific and ethical advice before submission.
- Germany is well prepared for the CTR 536/2014 and the EU MDR and IVDR.

#### **Further News and General Framework**

- The Association of MECs in Germany tries hard to harmonize procedures.
- > There is a joint working party with the NCAs.
- ➤ Substantial Amendments are treated in the same way as a trial application, → NCA and MEC.
- ➤ MECs are involved in the assessment of SUSARs and the annual safety reports.
- ➤ The involvement of MECs in the supervision of ongoing trials is not very developed.

## Impact of the CTR - Institutionally

- > ECs get marginalized
- > ECs get dependent to the government
  - registration etc., by-laws
  - loose the right to provide their own statement re Part I and have to collaborate with the NCA
  - loose their financial autonomy
- > The honorary sytem of ECs is at risk, the impact of the individual member weakens.
- The final decision (Art.8) is done by the NCA.

  ARBEITSKREIS MEDIZINISCHER ETHIK-ROMMISSIONEN

## Impact of the CTR - Workwise

- Considerable strain due to very short timelines.
- No more (oral) discussions with the sponsor, communication in writing(foreign language) only.
- > Increased affinity to IT-structured work-flow needed.
- More communication and probably compromising with NCAs.
- > ECs have to be available 365 days/year.



#### **Conclusions**

- ✓ Due to the CTR the ECs will loose a considerable part of their independence from the government: The government defines the registration requirements, the tasks and the fees of ECs.
- ✓ Many procedures have been standardized but the scope of the tasks of ECs is now completely up to the Member States – a serious step backwards compared to the CTD 2001/20/EU.

#### **Conclusions**

- ✓ In Germany the MECs are responsibly involved in the assessment of Part I AND II.
- ✓ The cooperation between NCA and EC has been tested in about 190 authorisation dossiers under the conditions of the CTR.
- ✓ The Implementation of the CTR is well prepared in Germany.

#### References

 Hasford J. The impact of the EU Regulation 536/2014 on the tasks and functioning of ethics committees in Germany. Bundesgesundheitsblatt 2017: 60; 830-835.

 <u>Sudhop T, Grass G, Wessler I:</u> Gemeinsames Pilotprojekt von Bundesoberbehörden und Ethikkommissionen zur Umsetzung der EU-Verordnung zu klinischen Prüfungen. Bundesgesundheitsblatt 2017: 60; 817–825.